Core Viewpoint - The Hang Seng Healthcare Index has shown strong performance, with significant increases in constituent stocks, indicating a positive trend in the healthcare sector [1][2]. Group 1: Market Performance - As of July 3, 2025, the Hang Seng Healthcare Index rose by 1.67%, with notable gains from stocks such as Huahao Zhongtian Pharmaceutical-B (+16.97%) and Ascentage Pharma-B (+7.11%) [1]. - The Hang Seng Healthcare ETF (Jia Shi, 159557) increased by 1.48% [1]. - The ETF recorded a turnover of 6.64% and a transaction volume of 21.35 million yuan, with an average daily transaction volume of 46.55 million yuan over the past month [2]. Group 2: Fund Performance - The latest scale of the Hang Seng Healthcare ETF reached 315 million yuan, marking a one-year high, with the latest share count at 221 million, also a three-month high [2]. - The ETF has seen a net inflow of 2.048 million yuan recently [2]. - Over the past year, the net value of the ETF has increased by 68.77%, ranking 16th out of 122 QDII equity funds, placing it in the top 13.11% [2]. Group 3: Valuation Metrics - The current price-to-earnings ratio (PE-TTM) of the Hang Seng Healthcare Index is 27.19, which is in the 9.23rd percentile over the past three years, indicating a valuation lower than 90.77% of the historical data [2]. Group 4: Sector Composition - The top ten weighted stocks in the Hang Seng Healthcare Index account for 57.72% of the index, including companies like Innovent Biologics, BeiGene, and WuXi Biologics [3][5]. - The top stocks have shown varied performance, with notable increases in companies like XinDa Biologics (+6.12%) and Kangfang Biologics (+6.95%) [5]. Group 5: Industry Outlook - According to Xiangcai Securities, the domestic innovative drug industry is expected to reach a turning point in 2025, shifting from capital-driven to profit-driven growth, presenting opportunities for both performance and valuation recovery [6]. - The commercialization of innovative products and the acceleration of research outcomes are expected to support market recovery [6].

Core Insights - The Chinese innovative drug sector is experiencing significant growth, particularly in overseas markets, marking a pivotal moment in 2025 as it gains global competitiveness [1] - The Hong Kong stock market's innovative drug index has shown impressive returns, making it a standout performer in the first half of 2025 [1] Group 1: Innovative Drug Development - Business Development (BD) refers to the strategic efforts to expand a company's market presence, while License-out is a key form of BD involving the authorization of drug rights to multinational companies [2] - The number and value of License-out transactions by Chinese pharmaceutical companies have been on the rise, reaching a historical peak of $52.3 billion in 2024, with $4.1 billion in upfront payments [5] - A notable example includes the collaboration between Innovent Biologics and Pfizer, which set a record with an upfront payment of $1.25 billion and potential milestone payments of up to $4.8 billion for a PD-1/VEGF bispecific antibody [7] Group 2: Market Dynamics - The global innovative drug market is vast, with China accounting for only 3% while the U.S. dominates with over 50%, making U.S. market entry crucial for Chinese companies [8] - The New-Co model, which involves forming new companies to attract external investment for drug development, is gaining traction in China, contrasting with the License-out model [8] Group 3: Industry Events and Trends - Major international oncology conferences such as ASCO, AACR, and ESMO serve as critical platforms for pharmaceutical companies to showcase their innovations and gauge industry trends [9] - At the 2025 ASCO conference, Chinese researchers led over 70 abstracts, a historic high compared to just one a decade ago, indicating a rapid advancement in the sector [11] Group 4: Drug Classification - First-in-class (FIC) drugs represent the highest value in innovative pharmaceuticals, while other categories include Best-in-class and Me-better, which are variations of existing drugs [12] - Chinese innovative drugs have achieved FIC breakthroughs in areas like bispecific antibodies and ADCs, positioning them as leaders in specific niches [12] Group 5: Investment Landscape - The introduction of Chapter 18A by the Hong Kong Stock Exchange allows unprofitable biotech companies to list, attracting numerous mainland innovative drug firms [27] - The A-share market has seen a relatively subdued performance in innovative drugs compared to Hong Kong, but there is potential for growth as more unprofitable yet promising companies may list on the STAR Market [29]

Market Overview - The Hang Seng Index (HSI) has shown a strong performance over the past six months, starting at 19,600 and reaching a high of 24,800, with a current level around 24,200, indicating a fluctuation of over 5,000 points [1] - The pharmaceutical sector has been the best-performing industry, with notable stocks like Kangfang Biotech (9926), China Biologic Products (1177), and WuXi Biologics (2269) showing exceptional gains [1] - Technology stocks, particularly Xiaomi (01810), have also performed well, with a 74% increase, while NetEase (09999) and Kuaishou (01024) saw gains of 50% and 48%, respectively [1] IPO and Derivative Market - The overall Hong Kong stock market has strengthened significantly in the first half of the year compared to 2023, with notable IPOs such as CATL and increased interest in consumer stocks like Pop Mart (9992) [2] - The issuance of structured products has been active, with the market responding to stock price movements, particularly for high-performing stocks [2] Investment Signals - The current sentiment in the market shows a bullish outlook, with 70% of investors holding bullish positions in HSI bull certificates, while 30% are bearish [5] - Caution is advised as the market lacks strong momentum, and there may be a potential pullback to around 23,700 before any further upward movement [5] Stock Analysis - Xiaomi has recently launched a new product, the YU7 car, which received 200,000 orders within an hour, driving its stock price to around 61, marking a 74% increase in the first half of the year [9] - BYD's sales in June reached 382,000 vehicles, with stock prices showing resilience around the 120 mark, indicating potential for further gains [13] - China Construction Bank has seen its stock price rise above 8, with a strong buy signal indicated for its derivatives [16] - China General Nuclear Power (01816) has shown a steady upward trend, with a buy signal for its structured products [19]

Core Viewpoint - The CESHKB index has shown significant growth, with a year-to-date increase of 64.30%, indicating a strong performance in the biotechnology sector listed in Hong Kong [1][2]. Group 1: Index Performance - The CESHKB index opened high and fluctuated, closing at 7388.22 points with a trading volume of 12.985 billion [1]. - Over the past month, the CESHKB index has risen by 14.05%, and over the last three months, it has increased by 17.80% [1]. Group 2: Index Composition - The CESHKB index is compiled by China Securities Index Co., Ltd. under the commission of China Securities Trading Service Co., Ltd., reflecting the overall performance of biotechnology companies listed in Hong Kong [1]. - The top ten holdings in the CESHKB index include: - CanSino Biologics (10.49%) - Innovent Biologics (9.9%) - WuXi Biologics (9.73%) - 3SBio (8.86%) - BeiGene (8.81%) - Zai Lab (5.86%) - WuXi AppTec (5.85%) - Kelun-Biotech (5.1%) - Genscript Biotech (4.42%) - Ascentage Pharma-B (4.15%) [1]. Group 3: Market and Industry Overview - The CESHKB index is entirely composed of companies listed on the Hong Kong Stock Exchange, with a 100% representation in the healthcare sector [2].

Core Viewpoint - The China Securities Index for Hong Kong Stock Connect in the healthcare sector has shown significant growth, with a year-to-date increase of 49.37% [1]. Group 1: Index Performance - The China Securities Index for Hong Kong Stock Connect Healthcare Composite Index (930965) rose by 0.85%, reaching 3051.69 points, with a trading volume of 18.538 billion yuan [1]. - Over the past month, the index has increased by 9.40%, and over the last three months, it has risen by 15.29% [1]. Group 2: Index Composition - The index comprises 50 liquid and large-cap healthcare companies listed under the Hong Kong Stock Connect, reflecting the overall performance of these securities [1]. - The index was established on November 14, 2014, with a base point of 3000.0 [1]. Group 3: Top Holdings - The top ten holdings in the index are as follows: - Innovent Biologics (9.96%) - WuXi Biologics (9.13%) - BeiGene (8.86%) - CanSino Biologics (5.83%) - CSPC Pharmaceutical Group (5.6%) - China Biologic Products (5.26%) - JD Health (4.73%) - 3SBio (4.07%) - Hansoh Pharmaceutical (3.15%) - Zai Lab (2.69%) [1]. Group 4: Market and Sector Allocation - The index's holdings are entirely composed of securities listed on the Hong Kong Stock Exchange, with a 100% allocation to the healthcare sector [1].

- Model Name: Hong Kong Stock Selection 20 Portfolio; Model Construction Idea: The model selects the top 20 stocks with the highest scores based on four types of factors (technical, capital, fundamental, and analyst expectations) from the Hong Kong Stock Connect sample stocks and constructs an equal-weighted portfolio at the end of each month; Model Construction Process: The model uses the Hong Kong Composite Index (HKD) (930930.CSI) as the benchmark. The specific construction process involves selecting the top 20 stocks with the highest scores based on the four types of factors and constructing an equal-weighted portfolio at the end of each month[3][37][39]; Model Evaluation: The model has shown excellent performance in the Hong Kong Stock Connect sample stocks[37] - Factor Name: Technical Factors; Factor Construction Idea: Technical factors are constructed based on the price and volume data of stocks; Factor Construction Process: The specific construction process involves calculating various technical indicators such as moving averages, relative strength index (RSI), and moving average convergence divergence (MACD) to evaluate the stock's price trend and momentum[37][38]; Factor Evaluation: Technical factors have shown good performance in the Hong Kong Stock Connect sample stocks[37] - Factor Name: Capital Factors; Factor Construction Idea: Capital factors are constructed based on the capital flow data of stocks; Factor Construction Process: The specific construction process involves calculating the net capital inflow and outflow of stocks to evaluate the stock's capital flow trend[37][38]; Factor Evaluation: Capital factors have shown good performance in the Hong Kong Stock Connect sample stocks[37] - Factor Name: Fundamental Factors; Factor Construction Idea: Fundamental factors are constructed based on the financial data of stocks; Factor Construction Process: The specific construction process involves calculating various financial ratios such as price-to-earnings (P/E) ratio, return on equity (ROE), and total market value to evaluate the stock's financial health and valuation[37][38]; Factor Evaluation: Fundamental factors have shown good performance in the Hong Kong Stock Connect sample stocks[37] - Factor Name: Analyst Expectation Factors; Factor Construction Idea: Analyst expectation factors are constructed based on the analyst ratings and target prices of stocks; Factor Construction Process: The specific construction process involves collecting and analyzing the analyst ratings and target prices of stocks to evaluate the stock's future performance expectations[37][38]; Factor Evaluation: Analyst expectation factors have shown good performance in the Hong Kong Stock Connect sample stocks[37] Model Backtest Results - Hong Kong Stock Selection 20 Portfolio, Annualized Excess Return: 13.3%, Excess Return Volatility Ratio: 1.0[4][40][41] Factor Backtest Results - Southbound Capital, Average Return: 25.7%[32][36] - Foreign Capital, Average Return: 13.5%[32][36] - Domestic Capital, Average Return: 14.0%[32][36] - Hong Kong Capital and Others, Average Return: 10.2%[32][36]

7月2日，A股窄幅整理，港股持续走强，创新药概念延续活跃。股票型ETF中，港股创新药ETF （513120）早盘半日成交额超38.51亿元，居股票型ETF首位，下午开盘后成交额持续在股票型ETF中领 先。从走势看，港股创新药ETF年内涨幅超60%，位居全市场ETF涨幅榜TOP5；从资金流向看，港股创 新药ETF近三周（6.9-6.27）连续获资金净买入，期间合计"吸金"超31亿元，最新规模超134亿元，是目 前全市场规模最大的港股创新药主题指数基金。 中银证券指出，交易层面，港股映射催化，创新药仍具长期投资价值。"18A"政策催化下，医疗企业密 集赴港上市，这些企业聚焦前沿、代表着未来的医疗产业方向，受到市场广泛关注，同时作为离岸市 场，美元贬值、资金回流新兴市场之下，港股也受到资金催化，港股创新药板块表现亮眼，映射逻辑 下，A股创新药也受到一定带动。综合来看，创新药受到基本面与交易面多重催化，后续行情仍然可 期。 （文章来源：每日经济新闻） 把握创新药行情投资机遇，港股创新药ETF（513120）凭借三大优势成为资金布局首选：一是跟踪中证 香港创新药指数，指数申万二级生物制品和化学制药合计权重超过92.5% ...

Core Viewpoint - The Hang Seng Healthcare Index has shown strong performance, with significant gains in constituent stocks, indicating a positive trend in the healthcare sector [1][3]. Group 1: Market Performance - As of July 2, 2025, the Hang Seng Healthcare Index rose by 1.75%, with notable increases in stocks such as SiPai Health (+46.34%) and HuaHao ZhongTian Pharma-B (+22.68%) [1]. - The Hang Seng Healthcare ETF (159557) experienced a 0.62% increase, marking its third consecutive rise [1]. - The trading volume for the Hang Seng Healthcare ETF was active, with a turnover of 43.37 million yuan and a turnover rate of 14.33% [3]. Group 2: Fund Performance - The Hang Seng Healthcare ETF has seen a significant increase in scale, growing by 5.73 million yuan over the past two weeks, ranking first among comparable funds [3]. - The ETF's net asset value increased by 66.32% over the past year, placing it 16th out of 119 QDII equity funds, which is in the top 13.45% [3]. - The ETF has recorded a maximum monthly return of 23.84% since its inception, with an average monthly return of 7.67% during rising months [3]. Group 3: Valuation Metrics - The current price-to-earnings ratio (PE-TTM) of the Hang Seng Healthcare Index is 27.1, which is at a historical low, being in the 8.88th percentile over the past three years [3]. - The top ten weighted stocks in the Hang Seng Healthcare Index account for 57.72% of the index, with notable companies including Innovent Biologics and BeiGene [4][6]. Group 4: Industry Outlook - Recent measures from the National Healthcare Security Administration and the National Health Commission aim to support the high-quality development of innovative drugs, focusing on R&D support and inclusion in insurance directories [6]. - Analysts from Huayuan Securities and Xiangcai Securities express optimism for the innovative drug sector, anticipating a shift from capital-driven growth to profit-driven growth in 2025 [7].

Core Viewpoint - The recent adjustments in the commercial health insurance drug directory signify an important step for the commercial health insurance market's entry, enhancing its role in the multi-tiered medical security system in China [4][5]. Group 1: Market Performance - The Hang Seng Healthcare Index (HSHCI) rose by 2.32% as of July 2, 2025, with notable increases in constituent stocks such as SiPai Health (00314) up 43.53% and Huahao Zhongtian Pharmaceutical-B (02563) up 41.04% [3]. - The Hang Seng Healthcare ETF (513060) increased by 0.87%, marking its third consecutive rise, with a latest price of 0.58 yuan [3]. - Over the past week, the Hang Seng Healthcare ETF has accumulated a rise of 0.53% [3]. Group 2: Liquidity and Trading Volume - The Hang Seng Healthcare ETF had a turnover rate of 2.96% during the trading session, with a transaction volume of 247 million yuan [3]. - The average daily trading volume for the ETF over the past month was 2.139 billion yuan, ranking it first among comparable funds [3]. Group 3: Fund Performance and Metrics - The latest scale of the Hang Seng Healthcare ETF reached 7.997 billion yuan, placing it in the top third among comparable funds [4]. - The ETF's financing buy amount was 94.5905 million yuan, with a financing balance of 292 million yuan [4]. - The net value of the ETF has increased by 15.65% over the past two years, with a maximum single-month return of 28.34% since inception [4]. Group 4: Risk and Return Analysis - As of July 1, 2025, the ETF's relative drawdown against the benchmark was 0.45%, the smallest among comparable funds, with a recovery period of 43 days [5]. - The management fee for the ETF is 0.50%, and the custody fee is 0.15% [5]. - The tracking error for the ETF over the past year was 0.070%, the highest tracking precision among comparable funds [5]. Group 5: Valuation Metrics - The latest price-to-earnings ratio (PE-TTM) for the Hang Seng Healthcare Index is 27.1, indicating a valuation below 91.12% of the time over the past three years, suggesting a historical low [5]. - The top ten weighted stocks in the HSHCI account for 57.72% of the index, including companies like Innovent Biologics (01801) and BeiGene (06160) [5].

Market Overview - On June 30, the Hong Kong stock market experienced a slight pullback, with the Hang Seng Index falling by 212 points or 0.9% to close at 24,072 points. The Hang Seng Tech Index decreased by 0.7% to 5,302 points. The total market turnover was HKD 242.2 billion, with a net inflow of HKD 5.22 billion through the Stock Connect [1] - Key blue-chip stocks in sectors such as banking, insurance, and the internet generally retreated, while consumer, telecommunications, and industrial blue-chip stocks rose. Notably, the biopharmaceutical, media entertainment, gold retail, and digital asset sectors performed well [1] Macro Dynamics - In the U.S., May PCE and core PCE rose by 2.3% and 2.7% year-on-year, respectively, showing a slight recovery from April. The actual year-on-year growth rate of personal disposable income for U.S. residents fell to 1.7%, while actual year-on-year growth in personal consumption expenditures slowed to 2.2%, the lowest since February of the previous year [2] - In China, new home sales continued to decline year-on-year, with a reported 2.99 million square meters sold in 30 major cities, down 24.7% year-on-year [2] Industry Dynamics - In the consumer sector, the stock price of Lao Pu Gold (6181 HK) rose by 15% after the expiration of a one-year lock-up period, driven by the opening of new stores in Shanghai and Singapore. The current valuation is approximately 40 times the 2025 earnings [3] - The Hang Seng Healthcare Index increased by 0.8%, with the National Healthcare Security Administration recently issuing guidelines for the adjustment of the basic medical insurance directory and innovative drug directory for commercial health insurance [4] - The renewable energy sector saw a general decline in Hong Kong stocks, but the photovoltaic sector performed well, with companies like Xinyi Solar (968 HK) and Flat Glass Group (6865 HK) rising by 4.2% to 7.6% [5] Strategic Outlook - The report from Zhongtai International forecasts a bullish outlook for the Hong Kong stock market in 2025, driven by a technical bull market and favorable policies. The Hang Seng Index is expected to have a target price adjustment from 23,000 points to 24,500 points by the end of the year, with an anticipated increase in earnings per share of 8.5% and 8.3% for 2025 and 2026, respectively [6] - The report highlights that the Hong Kong stock market is likely to attract cross-market capital flows due to a weaker U.S. dollar and valuation opportunities, with a net inflow of HKD 708.1 billion from southbound funds from the beginning of the year to the end of June [8] - The report identifies ten key stocks for the second half of the year, including Tencent (700 HK), SMIC (981 HK), and China Ping An (2318 HK) [10]